<DOC>
	<DOCNO>NCT02467010</DOCNO>
	<brief_summary>Bortezomib cyclophosphamide combination dexamethasone already demonstrate high response rate refractory multiple myeloma . Low dose continuous cyclophosphamide , also call metronomic scheduling , minimize toxic side effect eliminate obligatory rest period . Combining cyclophosphamide bortezomib might target distinct aspect myeloma functionality . The objective present study whether patient refractory relapsed multiple myeloma reinduction bortezomib , cyclophosphamide dexamethasone benefit maintenance therapy bortezomib cyclophosphamide acceptable side-effects . Recently two study show thalidomide maintenance therapy might improve EFS one study also OS .</brief_summary>
	<brief_title>Relapse Myeloma ; Cyclofosfamide ; Bortezomib ; Maintenance</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 year Stage IIIII Multiple Myeloma Relapse primary refractory disease initial chemotherapy WHO performance status 0 2 Life expectancy least 6 week ANC ( absolute neutrophil count ) ≥ 1.0x109/l ( ≥ 0.5x109/l , due bone marrow infiltration malignancy ) Platelet count ≥ 75x109/l ≥ 50x109/l , due bone marrow infiltration malignancy ) Written inform consent ( present patient 's file ) Patient able willing use adequate contraception therapy least 1 month study Patient ability understand requirement study Previous treatment bortezomib Urine production &lt; 1.5 l/24h Preexistent polyneuropathy ( grade 2 high , accord CTCAE 3.0 ) Pregnancy positive pregnancy test study 1 month final dose thalidomide History active malignancy past 5 year exception basal carcinoma skin ) Active uncontrolled infection Additional uncontrolled serious medical psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>dexamethason</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>